Matrixx Initiatives, Inc. Says FDA Unwilling to Change Stance on Zicam

Reuters -- Matrixx Initiatives Inc said the U.S. health regulator has indicated that it is unwilling to reverse its position regarding the warning letter issued on company's nasal versions of Zicam cold remedy.
MORE ON THIS TOPIC